Slide 1: Dimerix Investor Webinar
For Immediate Release DIMERIX INVESTOR WEBINAR Investor Webinar | Thu, 1 May 2025 - 11am AEST You are invited to register using this link: https://us06web.zoom.us/webinar/register/WN_9o26BBaCSta4S6rwA02yRQ Participants may submit questions at registration or during the session MELBOURNE, Australia,
Slide 2: About Dimerix
About Dimerix Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focussed on developing its proprietary Phase 3 product candidate DMX-200 (QYTOVRA® in some territories),
Slide 3: Licensing Webinar - US
ACTIONS ww Dimerix Licensing Webinar - US 1 May 2025 Authorised for lodgement by the Board of the Company
Slide 4: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will
Slide 5: Overview
Overview | Phase 3 Four commercial licensing deals: “AU$1.4 billion in total upfront & potential development and sales milestone payments plus royalties? Global Opportunity Lead Drug Candidate * DMX-200 is currently in a Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS) * DMX-200
Slide 6: Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS) = Ktchoy vessels have to work Focal some Existing blood pressure medication harder under high pressure targets Step 1: angiotensin receptor if 4 ‘oo py 200 interrupts Step 2-the = i blocker (ARB) lowers blood pressure" igh blo inflammatory pathway to target
Slide 7: Key elements of Amicus partnership
Key elements of Amicus partnership Amicus acquires exclusive license to commercialise DMX-200 for all indications in United States Amicus will be responsible for preparation, submission and maintenance D IMerx Ke) receive. of the regulatory dossier in the United States, as well as all sales and cost
Slide 8: A Rare Company: Amicus Therapeutics
1 A Rare Company: A unique story in biotech with significant revenue growth and profitability #? Galafold’ «aw (migalastat) First Oral Precision Medicine for Fabry Disease $528M Total Revenue in FY 2024 Double-digit Revenue Growth 5 Pombiliti* (agcasiase alfa-atga) YOpfolda® (rilustat) 65 mg capsule
Slide 9: Dimerix & Amicus
[er Amicus & @ Dimerix Poised for success through strong strategic alignment Amicus is a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare dseases Amicus has a fully integrated regulatory, sales, reimbursement and marketing teams + Amic
Slide 10: Summary of licensing deals for DMX-200 to date
Summary of licensing deals for DMX-200 to date me Li ing deal: llectivel has successfully partnered DMX-200 across key markets i ereirol “AU$1.4 1 2| : Amicus. |ADVANZ ((%/taiba| /¥ Fuso onne United States EU, CA, AU, NZ GCC, Iraq Japan bi I I ie) n in total upfront and potential milestone fees plus
Slide 11: Potential for additional partnering opportunities
Potential for additional partnering opportunities ADVANZ Amicus Therapeutics Significant potential additional global value remains, as Dimerix pursues and progresses licensing opportunities with potential partners outside the licensed territories, including in Mainland China @ Dimerix
Slide 12: FSGS Clinical Study
(ASX:DXB) FSGS CLINICAL STUDY @ Dimerix acts PHASE 3 CLINICAL TRIAL
Slide 13: ACTION3 phase 3 clinical trial — next steps
@} ACTI 3 phase 3 clinical trial — next steps FSGS CLINICAL STUDY A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB Phase 3 Trial Timeli > > Open Label Extension 72 patients @ 35 weeks Part 3: Successful analysis ou
Slide 14: ACTION3 current status
Ory ACTIXAN3 current status FSGS CLINICAL STUDY Total number of patients required - anticipated H2 2025! 42 Patients enrolled over into Li 2 Open Label Extension Study? 185 Patients recruited, A randomised and dosed? ( Confirmed: Positive Type C meeting held in March 2025 with US Food & Drug Adminis
Slide 15: Corporate overview
Corporate overview meetin fy scree os Cash Balance (Mar25)* $17 million nq os a > z Market Capitalisation’ $269 million 2 H foo wl j j Share price! $0.48 : Total ordinary shares on issue’ 559,460,138 ° Se eee = -_ us ° Average Daily Liquidity by value for $1 million st 30 trading days? Past et Badin
Slide 16: Summary
Summary [Phase 3 |Global Opportunity . . . Lead Drug Candidate Four commercial licensing deals: * DMX-200 is currently in a Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS) * DMX-200 has orphan drug designation in key territories “AU$1.4 billion FSGS Indication ° FSGS is a rare d
Slide 17: Well positioned to deliver against strategic plan
wy Dimerix (ASX:DXB) SCAN ME WELL POSITIONED TO DELIVER AGAINST STRATEGIC PLAN ESG Statement Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve it